200 related articles for article (PubMed ID: 14750129)
21. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
22. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
Kang SH; Kang KW; Kim KH; Kwon B; Kim SK; Lee HY; Kong SY; Lee ES; Jang SG; Yoo BC
BMC Cancer; 2008 Oct; 8():286. PubMed ID: 18834540
[TBL] [Abstract][Full Text] [Related]
23. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
24. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
Talukder AH; Bagheri-Yarmand R; Williams RR; Ragoussis J; Kumar R; Raz A
Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
[TBL] [Abstract][Full Text] [Related]
25. Stroma cells: a novel target of herceptin activity.
Corsini C; Mancuso P; Paul S; Burlini A; Martinelli G; Pruneri G; Bertolini F
Clin Cancer Res; 2003 May; 9(5):1820-5. PubMed ID: 12738740
[TBL] [Abstract][Full Text] [Related]
26. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Ye D; Mendelsohn J; Fan Z
Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
28. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
29. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
30. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
31. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines.
Kauraniemi P; Hautaniemi S; Autio R; Astola J; Monni O; Elkahloun A; Kallioniemi A
Oncogene; 2004 Jan; 23(4):1010-3. PubMed ID: 14647448
[TBL] [Abstract][Full Text] [Related]
32. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
34. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
35. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
36. [Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro].
Tan K; Fan YX; Miao JX; Lü CW; Yan X; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):234-6. PubMed ID: 16503541
[TBL] [Abstract][Full Text] [Related]
37. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
Khalili P; Arakelian A; Chen G; Singh G; Rabbani SA
Oncogene; 2005 Oct; 24(44):6657-66. PubMed ID: 16091754
[TBL] [Abstract][Full Text] [Related]
38. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.
Blackburn E; Zona S; Murphy ML; Brown IR; Chan SK; Gullick WJ
Breast Cancer Res Treat; 2012 Jul; 134(1):53-9. PubMed ID: 22169894
[TBL] [Abstract][Full Text] [Related]
39. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.
Lane HA; Motoyama AB; Beuvink I; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S21-2. PubMed ID: 11521716
[TBL] [Abstract][Full Text] [Related]
40. [Killing effect of 131I-Herceptin on breast cancer cell lines in vitro].
Lin J; Luo RC; Li AM; Zhang JY; Lü CW; Yan X
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):663-6. PubMed ID: 15958303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]